Advertisement

Arthritis Associated with Alphavirus Infections: Dengue and Zika

  • Sergio Miguel Angel Toloza
  • Santiago Eduardo Agüero
Chapter

Abstract

Dengue virus (DENV) and Zika virus (ZIKV) are a cause of significant morbidity and mortality worldwide within specific regions of the world where they are endemic and susceptible to the occurrence of epidemics. The interaction between these viruses and other host factors (especially the immunocompetence) seems to influence the expression and severity of these conditions. The various clinical forms of both DENV and ZIKV are still being characterized phenotypically, serologically, and genetically together with the pathophysiological mechanisms leading to their protean clinical manifestations and complications. Arthralgias involving small and large joints occur frequently in DENV-affected patients, but typical arthritis is seldom found; accordingly, a physical exam of joints is often unremarkable. Joint pain may precede, appear simultaneously, or subsequently to the onset of fever, and might be masked by more prominent symptoms like backache, large-bone pain, and myalgias. The arthritic phenotype of DENV infection is still unknown, but it seems monoarticular, short-lived, and responsive to symptomatic treatment, whereas the articular manifestations of ZIKV infection are less severe. ZIKV is more likely to induce neurological complications and congenital abnormalities. Coinfection of DENV and ZIKV with chikungunya virus seems to lead to protracted arthritis manifestations and may be associated to a higher morbidity and mortality.

Keywords

Dengue Zika virus Arthritis phenotype Autoimmune diseases Pathophysiology Diagnosis Pregnancy Management Prevention 

References

  1. 1.
    Rigau-Pérez JG. The early use of break-bone fever (Quebranta huesos, 1771) and dengue (1801) in Spanish. Am J Trop Med Hyg. 1998;59(2):272–4.CrossRefGoogle Scholar
  2. 2.
    Gould E, Pettersson J, Higgs S, Charrel R, de Lamballerie X. Emerging arboviruses: why today? One Health. 2017;4:1–13.  https://doi.org/10.1016/j.onehlt.2017.06.001. eCollection 2017 Dec. Review.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Leta S, Beyene TJ, De Clercq EM, Amenu K, Kraemer MUG, Revie CW. Global risk mapping for major diseases transmitted by Aedes aegypti and Aedes albopictus. Int J Infect Dis. 2018;67:25–35.  https://doi.org/10.1016/j.ijid.2017.11.026. Epub 2017 Nov 28.CrossRefPubMedGoogle Scholar
  4. 4.
    World Health Organization. Dengue and severe dengue; 13 September 2018. Accessed online at https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.
  5. 5.
    World Health Organization. Situation Report Zika Virus Microcephaly Guillain-Barré Syndrome 10 March 2017 Data as of 9 March 2017. Accessed online at http://apps.who.int/iris/bitstream/handle/10665/254714/zikasitrep10Mar17-eng.pdf;jsessionid=BCE3098CD567B55EAAFDA1F9878FE731?sequence=1.
  6. 6.
    Song BH, Yun SI, Woolley M, Lee YM. Zika virus: History, epidemiology, transmission, and clinical presentation. J Neuroimmunol. 2017;308:50–64.CrossRefGoogle Scholar
  7. 7.
    Ngono AE, Shresta S. Immune response to Dengue and Zika. Annu Rev Immunol. 2018;26(36):279–308.CrossRefGoogle Scholar
  8. 8.
    Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14:1232–9.CrossRefGoogle Scholar
  9. 9.
    Montoya M, Collins M, Dejnirattisai W, Katzelnick LC, et al. Longitudinal analysis of antibody cross-neutralization following Zika Virus and Dengue Virus Infection in Asia and the Americas. J Infect Dis. 2018;218(4):536–45.CrossRefGoogle Scholar
  10. 10.
    Andrade PE, Coloma J, Michlmayr D, Balmaseda AL, Harris E. Zika and dengue virus specific and cross-reactive memory B cell responses. J Immunol. 2017;98(1 Suppl):214.Google Scholar
  11. 11.
    Cordeiro MT, Pena LJ, Brito CA, et al. Positive IgM for Zika virus in the cerebrospinal fluid of 30 neonates with microcephaly in Brazil. Lancet. 2016;387:1811–2.CrossRefGoogle Scholar
  12. 12.
    Bhatt S, Gething PW, Brady OJ, Messina JP, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504.CrossRefGoogle Scholar
  13. 13.
    World Health Organization and the Special Programme for Research and Training in Tropical Diseases (TDR). Dengue guidelines for diagnosis, treatment, prevention and control: new edition. Publication date: 2009. Accessed online at http://www.who.int/rpc/guidelines/9789241547871/en/.
  14. 14.
    World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: WHO; 1997. Accessed online at http://apps.who.int/iris/bitstream/10665/41988/1/9241545003_eng.pdf.Google Scholar
  15. 15.
    Centers for Disease Control and Prevention. Zika Virus Disease Q & A. Accessed at: https://www.cdc.gov/zika/about/questions.html.
  16. 16.
    Lozier MJ, Burke RM, Lopez J, Acevedo V, et al. Differences in prevalence of symptomatic Zika virus infection, by age and sex-Puerto Rico, 2016. J Infect Dis. 2018;217(11):1678–89.CrossRefGoogle Scholar
  17. 17.
    Adebajo AO. Dengue arthritis. Br J Rheumatol. 1996;35:909–10.CrossRefGoogle Scholar
  18. 18.
    Patil MM, Akki AS. Dengue arthritis in a child. Indian Pediatr. 2013;50(5):523–4.PubMedGoogle Scholar
  19. 19.
    Jayamali WD, Herath HMMTB, Kulatunga A. A young female presenting with unilateral sacroiliitis following dengue virus infection: a case report. J Med Case Rep. 2017;11(1):307.CrossRefGoogle Scholar
  20. 20.
    Kularatne SA, Gihan MC, Weerasinghe SC, Gunasena S. Concurrent outbreaks of Chikungunya and Dengue fever in Kandy, Sri Lanka, 2006-07: a comparative analysis of clinical and laboratory features. Postgrad Med J. 2009;85(1005):342–6.CrossRefGoogle Scholar
  21. 21.
    Bhaskar E, Sowmya G, Moorthy S. Musculoskeletal manifestations of dengue fever: is there a changing pattern? J Clin Rheumatol. 2012;18(2):102–3.CrossRefGoogle Scholar
  22. 22.
    Londhey V, Agrawal S, Vaidya N, Kini S, Shastri JS, Sunil S. Dengue and Chikungunya virus co-infections: the inside story. J Assoc Physicians India. 2016;64(3):36–40.PubMedGoogle Scholar
  23. 23.
    Halsey ES, Marks MA, Gotuzzo E, Fiestas V, Suarez L, Vargas J, Aguayo N, Madrid C, Vimos C, Kochel TJ, Laguna-Torres VA. Correlation of serotype-specific dengue virus infection with clinical manifestations. PLoS Negl Trop Dis. 2012;6(5):e1638.CrossRefGoogle Scholar
  24. 24.
    de Oliveira SA, Camacho LA, Bettini LR, Fernandes DG, Gouvea NA, Barros RA, Setúbal S, Siqueira MM. [The joint manifestations of exanthematous viroses]. Rev Soc Bras Med Trop. 1999;32:125–30.Google Scholar
  25. 25.
    Roimicher L, Ferreira OC Jr, Arruda MB, Tanuri A. Zika virus in the joint of a patient with rheumatoid arthritis. J Rheumatol. 2017;44(4):535.CrossRefGoogle Scholar
  26. 26.
    Duffy MR, Chen TH, Hancock WT, Powers AM, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360:2536–43.CrossRefGoogle Scholar
  27. 27.
    Cherabuddi K, Iovine NM, Shah K, White SK, Paisie T, Salemi M, Morris JG Jr, Lednicky JA. Zika and Chikungunya virus co-infection in a traveller returning from Colombia, 2016: virus isolation and genetic analysis. JMM Case Rep. 2016;3(6):e005072.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Silva KR, Bica BERG, Pimenta ES, Serafim RB, et al. Fatal human case of Zika and Chikungunya virus co-infection with prolonged viremia and viruria. Diseases. 2018;6(3):53.CrossRefGoogle Scholar
  29. 29.
    Read JS, Torres-Velasquez B, Lorenzi O, Rivera Sanchez A, et al. Symptomatic Zika virus infection in infants, children, and adolescents living in Puerto Rico. JAMA Pediatr. 2018;172(7):686–93.CrossRefGoogle Scholar
  30. 30.
    Li HM, Huang YK, Su YC, Kao CH. Increased risk of autoimmune diseases in dengue patients: a population-based cohort study. J Infect. 2018;77(3):212–9.  https://doi.org/10.1016/j.jinf.2018.03.014. Epub 2018 May 7.CrossRefPubMedGoogle Scholar
  31. 31.
    Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Rodríguez Y, Ramírez-Santana C, Anaya JM. Zika virus and autoimmunity. One-step forward. Autoimmun Rev. 2017;16(12):1237–45.  https://doi.org/10.1016/j.autrev.2017.10.008. Epub 2017 Oct 14. Review.CrossRefPubMedGoogle Scholar
  32. 32.
    Zea-Vera AF, Parra B. Zika virus (ZIKV) infection related with immune thrombocytopenic purpura (ITP) exacerbation and antinuclear antibody positivity. Lupus. 2017;26:890–2.CrossRefGoogle Scholar
  33. 33.
    Talib SH, Bhattu S, Bhattu R, Deshpande S, Dahiphale D. Dengue fever triggering systemic lupus erythematosus and lupus nephritis: a case report. Int Med Case Rep J. 2013;6:71–5.CrossRefGoogle Scholar
  34. 34.
    Rajadhyaksha A, Mehra S. Dengue fever evolving into systemic lupus erythematosus and lupus nephritis: a case report. Lupus. 2012;21(9):999–1002.CrossRefGoogle Scholar
  35. 35.
    Verdolin LD, Borner AR, Mussi H, Gismondi RA, Schau B, Ramos RC. Rhabdomyolysis associated with dengue fever in a lupic patient. Rev Bras Reumatol. 2014;54(4):318–21.CrossRefGoogle Scholar
  36. 36.
    Harris VK, Danda D, Murali NS, Das PK, Abraham M, Cherian AM, Chandy M. Unusual association of Kikuchi’s disease and dengue virus infection evolving into systemic lupus erythematosus. J Indian Med Assoc. 2000;98(7):391–3.PubMedGoogle Scholar
  37. 37.
    Kumar S, Iuga A, Jean R. Cardiac tamponade in a patient with dengue fever and lupus nephritis: a case report. J Intensive Care Med. 2010;25(3):175–8.CrossRefGoogle Scholar
  38. 38.
    de Souza SP, de Moura CG. Dengue mimicking a lupus flare. J Clin Rheumatol. 2010;16(1):47–8.CrossRefGoogle Scholar
  39. 39.
    Chen WH. An unusual transitory increase of lupus anticoagulant in dengue virus infection complicated with cerebral ischaemia. J Infect. 2006;52(3):e87–91.CrossRefGoogle Scholar
  40. 40.
    Santosa A, Poh Z, Teng GG. Delayed diagnosis of systemic lupus erythematosus due to misinterpretation of dengue serology. Scand J Rheumatol. 2012;41(1):77–9.CrossRefGoogle Scholar
  41. 41.
    Wiwanitkit V. Delayed diagnosis of systemic lupus erythematosus due to misinterpretation of dengue serology: comments on the article by Santosa et al. Scand J Rheumatol. 2012;41(5):410–1.CrossRefGoogle Scholar
  42. 42.
    Zainal N, Tan KK, Johari J, Hussein H, Wan Musa WR, Hassan J, Lin YS, AbuBakar S. Sera of patients with systemic lupus erythematosus cross-neutralizes dengue viruses. Microbiol Immunol. 2018;62(10):659–72.CrossRefGoogle Scholar
  43. 43.
    Morel Z, Ramírez A. Autoimmune response in children with dengue. Case reports. Reumatol Clin. 2014;10(4):257–9.CrossRefGoogle Scholar
  44. 44.
    Palacios-Cuervo F, Calderón-Rivera A, Espinal-Reyes F, Canelo-Aybar C. Autoimmunity in dengue: literature review. Reumatol Clin. 2016;12(3):173–4.CrossRefGoogle Scholar
  45. 45.
    Colman N, Ojeda A, Yinde Y, Aquino A, Duarte M. Impacto de la infeccion por Dengue en pacientes con enfermedades autoinmunes. Revisión de casos. Rev Par Reumatol. 2017;3(1):20–4.Google Scholar
  46. 46.
    Agüero S, Toloza S, Lejtman N, Orellana Barrera S, Guaraz G. Manifestaciones clínicas y bioquímicas asociadas a infección por virus del dengue en pacientes con enfermedades reumáticas durante un brote epidémico en la provincia de Catamarca, República Argentina. Rev Arg Reumatol. 2011;22(3):14–28.Google Scholar
  47. 47.
    de Abreu MM, Maiorano AC, Tedeschi SK, Yoshida K, Lin TC, Solomon DH. Outcomes of lupus and rheumatoid arthritis patients with primary dengue infection: a seven-year report from Brazil. Semin Arthritis Rheum. 2018;47(5):749–55.CrossRefGoogle Scholar
  48. 48.
    Deligny C, de Bandt M, Dehlinger V, Numéric P, Cabié A, Lombard F, Polomat K, JeanBaptiste G, Arfi S. Dengue fever in patients under biologics. J Clin Virol. 2014;61(3):442–3.CrossRefGoogle Scholar
  49. 49.
    Wu WL, Ho LJ, Chen PC, Tsai YT, Hsu ST, Chang DM, Lai JH. Immunosuppressive effects and mechanisms of leflunomide in dengue virus infection of human dendritic cells. J Clin Immunol. 2011;31(6):1065–78.CrossRefGoogle Scholar
  50. 50.
    Mancera-Páez O, Román GC, Pardo-Turriago R, Rodríguez Y, Anaya JM. Concurrent Guillain-Barré syndrome, transverse myelitis and encephalitis post-Zika: a case report and review of the pathogenic role of multiple arboviral immunity. J Neurol Sci. 2018;395:47–53.CrossRefGoogle Scholar
  51. 51.
    Li GH, Ning ZJ, Liu YM, Li XH. Neurological manifestations of dengue infection. Front Cell Infect Microbiol. 2017;7:449.CrossRefGoogle Scholar
  52. 52.
    Dalugama C, Shelton J, Ekanayake M, Gawarammana IB. Dengue fever complicated with Guillain-Barré syndrome: a case report and review of the literature. J Med Case Rep. 2018;12(1):137.CrossRefGoogle Scholar
  53. 53.
    Malik S, Saran S, Dubey A, Punj A. Longitudinally extensive transverse myelitis following dengue virus infection: a rare entity. Ann Afr Med. 2018;17(2):86–9.CrossRefGoogle Scholar
  54. 54.
    Herath HMM, Hewavithana JS, De Silva CM, Kularathna OAR, Weerasinghe NP. Cerebral vasculitis and lateral rectus palsy - two rare central nervous system complications of dengue fever: two case reports and review of the literature. J Med Case Rep. 2018;12(1):100.CrossRefGoogle Scholar
  55. 55.
    Kamoi K, Mochizuki M, Ohno-Matsui K. Dengue fever-associated necrotizing scleritis: a case report with long-term follow-up. Medicine (Baltimore). 2018;97(32):e11875.CrossRefGoogle Scholar
  56. 56.
    Vouga M, Baud D. Imaging of congenital Zika virus infection: the route to identification of prognostic factors. Prenat Diagn. 2016;36(9):799–811.CrossRefGoogle Scholar
  57. 57.
    Olafuyi O, Badhan RKS. Dose optimisation of chloroquine by pharmacokinetic modelling during pregnancy for the treatment of Zika virus infection. J Pharm Sci. 2019;108(1):661–73. pii: S0022-3549(18)30689-0.CrossRefGoogle Scholar
  58. 58.
    Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, et al. The global burden of dengue: a analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(6):712–23.CrossRefGoogle Scholar
  59. 59.
    Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis. 2016 Aug;16(8):935–41.CrossRefGoogle Scholar
  60. 60.
    World Health Organization. Emergencies: one year into the Zika outbreak: how an obscure disease became a global health emergency. Accessed at: http://www.who.int/emergencies/zika-virus/articles/one-year-outbreak/en/index5.html.
  61. 61.
    Plourde AR, Bloch EM. A literature review of Zika virus. Emerg Infect Dis. 2016;22(7):1185–92.CrossRefGoogle Scholar
  62. 62.
    Tebas P, Roberts CC, Muthumani K, Reuschel EL, et al. Safety and immunogenicity of an anti-Zika virus DNA vaccine - preliminary report. N Engl J Med. 2017;  https://doi.org/10.1056/NEJMoa1708120.
  63. 63.
    World Health Organization. Dengue vaccine: WHO position paper, July 2016 - recommendations. Vaccine. 2017;35(9):1200–1.CrossRefGoogle Scholar
  64. 64.
    World Health Organization. Questions and answers on dengue vaccines; 20 April 2018. Accessed at: https://www.who.int/immunization/research/development/dengue_q_and_a/en/.
  65. 65.
    Eppes C, Rac M, Dunn J, Versalovic J, et al. Testing for Zika virus infection in pregnancy: key concepts to deal with an emerging epidemic. Am J Obstet Gynecol. 2017;216(3):209–25.CrossRefGoogle Scholar
  66. 66.
    Jentes ES, et al. Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians. J Travel Med. 2016;23(6)CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Sergio Miguel Angel Toloza
    • 1
  • Santiago Eduardo Agüero
    • 2
  1. 1.Health Statistics, Ministry of HealthProvince of CatamarcaArgentina
  2. 2.Centro de Rehabilitación Nivel II AmpliadoProvince of CatamarcaArgentina

Personalised recommendations